Experimental senolytic peptide · Fact sheet
FOXO4-DRI
Also known as FOXO4 D-retro-inverso peptide
FOXO4-DRI is an experimental peptide designed to disrupt a survival mechanism in senescent cells. Mouse and cell results do not establish safe human rejuvenation or a longevity regimen.
What is FOXO4-DRI?
Senescent cells stop dividing but can remain metabolically active. FOXO4-DRI interferes with the FOXO4–p53 interaction in experimental systems.
Its reversed D-amino-acid design is not the same as taking the natural FOXO4 protein.
Benefits & claims
Interest centers on clearing senescent cells and restoring tissue function. Senescence also has normal biological roles, so selective cell removal needs careful clinical testing.
What the evidence supports
- The original study improved selected measures of tissue function in mouse models of aging or chemotherapy injury.
- Later work reported effects on senescent Leydig cells and reproductive measures in aged mice.
- These findings do not demonstrate longer human life, safer testosterone production or established rejuvenation.
Research areas
- Cellular senescence
- Senolysis
- Aged-mouse tissue function
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for FOXO4-DRI. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Senescent cells stop dividing but can remain metabolically active. FOXO4-DRI interferes with the FOXO4–p53 interaction in experimental systems.
Formulation differences
- Its reversed D-amino-acid design is not the same as taking the natural FOXO4 protein.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Human benefit and adverse effects
- Which senescent cells are removed and which are spared
- Long-term tissue and cancer-related consequences
Side effects & risks
- Human repeated-exposure safety, tissue selectivity and immune reactions remain inadequately established.
- A strategy involving p53-linked cell survival requires assessment of effects on healthy tissue and tumor surveillance; the cited animal studies cannot quantify those human risks.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchThe original paper reported cell-selective killing and improvements in some mouse outcomes. Later mouse studies explored Leydig cells and spermatogenesis; none establishes human anti-aging benefit.
Studies
Cell and mouse work on senescent-cell survival and tissue homeostasis.
Preclinical testosterone and testicular-microenvironment findings.
Aged-mouse reproductive study, not human evidence.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
FOXO4-DRI has no FDA-approved therapeutic product. The cited efficacy experiments are preclinical, including work in aged mice.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Human benefit and adverse effects
- Which senescent cells are removed and which are spared
- Long-term tissue and cancer-related consequences
Summary
These findings do not demonstrate longer human life, safer testosterone production or established rejuvenation.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedOriginal FOXO4-DRI experiments
Cell and mouse work on senescent-cell survival and tissue homeostasis.
- pubmedFOXO4-DRI and aged Leydig cells
Preclinical testosterone and testicular-microenvironment findings.